IDEXX LABORATORIES INC

Idexx Laboratories: Despite market volatility, the company’s AI‑powered diagnostics and recurring revenue model support Goldman Sachs’ Buy rating, offering investors a niche growth opportunity in veterinary health.

Idexx Laboratories’ $44B stock remains resilient, driven by expanding veterinary diagnostics, global growth, and cost‑efficiency, promising steady upward momentum.

Idexx Laboratories shares rise 0.38% at $557.93, trading below its 200‑day SMA and 52‑week range—an attractive entry point for investors eyeing veterinary diagnostics and innovation.